Cremaffin PLUS

Quick links to important sections

Cremaffin PLUS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cremaffin PLUS

Quick Facts

Property Description
Active ingredient Liquid Paraffin, Magnesium Hydroxide, Sodium Picosulfate
Form Oral Suspension / Emulsion
Pharmacological class Combination Laxative / Cathartic
Common use Relief of Constipation
Origin Synthetic and Mineral Salt Combination

Cremaffin PLUS: A Combination Laxative Emulsion

Cremaffin PLUS is a specialized pharmaceutical preparation classified as a Fixed-Dose Combination (FDC) cathartic, utilized for the management of intestinal sluggishness and infrequent bowel movements. The product is formulated as an oral suspension or emulsion, a liquid dosage form designed for ingestion via the oral route of administration. This combination drug belongs to the general pharmacological class of laxatives, acting primarily on the gastrointestinal tract to promote bowel evacuation in the treatment of severe or chronic constipation.

Composition of Active Ingredients: Lubricant, Osmotic, and Stimulant

The preparation is defined by its three distinct active ingredient(s): Liquid Paraffin, Magnesium Hydroxide (also known as Milk Of Magnesia), and Sodium Picosulfate. These components represent a strategic blend of agents with varied origins, combining the synthetic compounds Liquid Paraffin and Sodium Picosulfate with the naturally derived mineral salt, Magnesium Hydroxide. Saline laxatives like Magnesium Hydroxide act by attracting and retaining water in the intestinal lumen, increasing the water content of the stool.

General Purpose of Cremaffin PLUS

The general therapeutic purpose of Cremaffin PLUS is to resolve the difficulties associated with persistent or acute constipation by facilitating a soft, comfortable, and predictable return to bowel regularity. Stimulant laxatives, such as Sodium Picosulfate, increase the propulsive motor activity of the colon. This action, combined with the stool-softening and lubricating effects of the other ingredients, aims to ensure that the patient experiences comprehensive relief, typically providing resolution for periods of severe irregularity or when simpler laxatives have proven insufficient. The preparation’s core benefit is rooted in this integrated, triple-action approach to alleviating bowel movement irregularity.

Regulatory References

  1. Management of Constipation

What side effects are possible with Cremaffin PLUS?

Possible Side Effects and Safety Information

This section summarizes the officially documented safety profile of Cremaffin PLUS, strictly based on governmental regulatory documents and established pharmacological data. It is for informational purposes only and does not constitute medical advice.


Adverse Reactions

The most commonly reported adverse reactions are gastrointestinal in nature. These typically include diarrhea, abdominal cramps, abdominal pain, and abdominal discomfort, and are often dose-related.

Classification Examples of Adverse Reactions
Common Diarrhea, abdominal pain, abdominal discomfort, nausea, vomiting, dizziness.
Serious (Rare) Electrolyte imbalance (e.g., hypermagnesemia, hypokalemia), severe dehydration, renal impairment, cardiac arrhythmia, or seizures (primarily associated with excessive use/overdose).

Serious adverse effects are uncommon and primarily linked to prolonged use or overdose, which can lead to significant fluid and electrolyte imbalance requiring immediate medical attention. The magnesium component, Milk of Magnesia, specifically carries a risk of hypermagnesemia in patients with severely reduced kidney function.


Safety Restrictions and Limitations

Cremaffin PLUS is contraindicated in several specific situations to prevent severe adverse outcomes:

  • Intestinal obstruction or blockage.
  • Undiagnosed abdominal pain.
  • Severe kidney disease (due to the risk of magnesium toxicity).
  • Known hypersensitivity to any of the product's components.

Use of this product for longer than one week is generally not recommended without explicit medical guidance. Specific populations, including pregnant and breastfeeding women and those with existing cardiac conditions, should use the product with caution and under professional supervision. It should not be given to children except under strict medical instruction.

Overdose and Emergency Response

An overdose of Cremaffin PLUS involves the combined effects of its active components, primarily leading to severe fluid and electrolyte imbalance and Magnesium Intoxication (Hypermagnesemia). Immediate medical attention or contact with a Poison Control Center is required upon suspected overdose.

Overdose manifestations documented in regulatory sources include severe diarrhea, vomiting, profound thirst, and abdominal cramps. Systemic signs may present as hypotension, muscle weakness, and flushing. Life-threatening complications documented in regulatory sources include respiratory paralysis, heart block, and hypokalaemia resulting from excessive electrolyte loss. Severe hypermagnesemia may cause the disappearance of the patellar reflex. High doses of the picosulfate component have also been associated with colonic mucosal ischaemia.

When immediate medical help is sought, the regulatory documents detail specific management procedures. These include the provision of supportive care, the replacement of fluids and the correction of electrolyte imbalance. A specific antidote, an injectable calcium salt, is documented as required to counteract severe magnesium toxicity. Monitoring serum magnesium levels and clinical status is necessary, particularly in patients with pre-existing renal impairment, the elderly, and the young, due to their heightened risk of toxicity.

Therapeutic Uses of Cremaffin PLUS

What Cremaffin PLUS Treats: Main Uses and Benefits

Cremaffin PLUS is commonly used across therapeutic domains where additional symptomatic support for intestinal sluggishness and constipation is needed. This combination of stimulant and osmotic components may be part of symptomatic management to assist with bowel clearance. This formulation is used for managing symptoms that interfere with daily functioning, particularly those related to difficult evacuation, such as hard, dry stool, straining, and abdominal discomfort.

The combination is relevant for easing symptoms that are episodic or fluctuating, including those associated with persistent constipation, post-operative conditions where straining must be minimized, and managing chronic difficulty in elderly or bedridden patients.

“It helps maintain a sense of stability when symptoms are more noticeable.”

Its use may assist with reducing the noticeable physiological strain required during episodes of difficult evacuation. This supportive function contributes to easing the overall symptom load and **supports the patient during difficult episodes by easing distress.

Quick Fact: Symptomatic Support Focus
Primary Focus Hard stool and straining relief
Key Scenarios Post-operative care; management in limited mobility
Benefit Assists with easing the overall symptom load during difficult episodes.

Regulatory References

  1. MedlinePlus overview on combination laxatives

Eligibility and Restrictions for Use

Who Can and Cannot Use Cremaffin PLUS?

Eligibility for using the combination laxative Cremaffin PLUS is strictly defined by regulatory documents, focusing on patient age and pre-existing medical conditions.


Absolute Contraindications

Cremaffin PLUS must not be used by patients with the following conditions, as stated in official labeling:

  • Gastrointestinal Obstruction: Including ileus, bowel perforation, or toxic megacolon.
  • Acute Abdominal Pain: Undiagnosed severe abdominal pain, appendicitis, or similar acute surgical conditions.
  • Severe Renal Impairment: Due to the risk of magnesium accumulation (hypermagnesemia).
  • Severe Dehydration or uncorrected fluid/electrolyte abnormalities.
  • Hypersensitivity to Liquid Paraffin, Magnesium Hydroxide, or Sodium Picosulfate.

Restricted and Conditional Use

Population Group Regulatory Status Constraint Basis
Children (lt 18 years) Not Recommended Safety and efficacy not established in pediatrics.
Pregnancy/Lactation Use with Caution Lack of sufficient safety data; only use if benefit outweighs risk.
Older Adults (Geriatrics) Use with Caution Increased susceptibility to fluid and electrolyte changes.
Mild to Moderate Renal Impairment Use with Caution Slower magnesium clearance requires medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes potential interactions that may alter the effectiveness or absorption of co-administered medicines. Patients are advised to consult a healthcare professional regarding these combinations.


Interacting Medicines and Categories

Category or Specific Medicine Potential Interaction Implication
Antihypertensives (e.g., Captopril, Enalapril) Potential to alter the effect of the antihypertensive medication.
Antivirals (e.g., Atazanavir, Fosamprenavir) May reduce the effectiveness of either medicine.
Iron Preparations Decreased absorption of the Iron preparation; necessitates timing separation of doses.
Antiepileptics (e.g., Gabapentin, Phenytoin) Potential to affect drug levels or efficacy.
Lipid-lowering agents (e.g., Rosuvastatin) Potential for reduced effectiveness; close monitoring may be advisable.
Other Specific Medicines Interactions are also documented for Tetracycline, Prednisone, Albuterol, Aspirin, Furosemide, and Levothyroxine.

Procedural Constraints and Requirements

Due to the risk of altered drug absorption or efficacy—a pharmacokinetic concern—official documents mandate constraints on co-administration. For many combinations, the requirement is to inform the physician and conduct close monitoring or seek consultation for potential dose adjustments. Specifically, the absorption of Iron Preparations is reduced, requiring the patient to follow a regulatory instruction for separation of the timing of dosing to manage this interaction.

Mechanism of Action

How Cremaffin PLUS Works

The action of this medication is achieved through three integrated and peripheral mechanisms that modify the fluid environment and motility of the colon.


Neuromuscular Stimulation and Active Secretion

This domain centers on Sodium Picosulfate, which must first be converted by colonic bacterial enzymes into its active metabolite, BHPM. The metabolite directly stimulates colonic nerve endings and mucosa, resulting in increased propulsive muscle contractions (peristalsis) and enhanced secretion of water and electrolytes into the lumen.


Osmotic Fluid Retention

The second action is driven by Magnesium Hydroxide, an osmotic agent whose poorly absorbed Mg^2+ ions create a concentration gradient in the colon. This gradient draws water from the body’s tissues into the intestinal lumen, which results in a dual physiological consequence: softening the fecal mass and creating mechanical distension that provides a complementary mechanical stimulus to the peristaltic muscle reflex.


Physical Lubrication and Emollient Action

The mechanism of Liquid Paraffin is purely physical and passive. It acts as an emollient, coating the hard fecal mass and the intestinal lining. This physical layer significantly reduces the frictional resistance between the stool and the colon wall, and facilitates the egress of the softened, propelled mass due to the coordinated action of the other two ingredients.

Dosage and Administration Information

Cremaffin PLUS is administered exclusively via the oral route, formulated as a liquid suspension or emulsion. The administration protocol adheres to standardized volumetric guidelines, necessitating the use of a calibrated measuring device to ensure precise dose accuracy when measuring the prescribed amount. A necessary preparation step is mandated: the bottle must be thoroughly shaken before the measured volume is drawn, which ensures the uniform dispersion of the product's multiple components prior to ingestion.

The standard labeled regimen for adults (18 years and older) involves a single daily dose ranging from 15 mL to 30 mL. This Once Daily frequency is typically scheduled for bedtime administration, which is the high-level principle for managing the expected overnight action of the combined ingredients to facilitate a morning bowel movement. Dosage adjustments within this range are based on prescriptive guidance.

A critical administration constraint involves the product’s co-ingestion with other oral medications. To prevent interference with the absorption of concurrently taken drugs, the administration of Cremaffin PLUS must be separated by an interval of approximately three to four hours from any other oral medicinal products.

Furthermore, the product's usage is defined by two key restrictions: duration and age. The continuous administration of this combination laxative is designated for short-term use only, and generally should not extend beyond seven consecutive days. Use is strictly restricted to the adult patient population (18 years and older), as its administration guidelines are not established for pediatric use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Evidence and Reported Outcomes

Research has explored the drug's proposed effect that the research evaluated. The primary evidence base comes from a series of clinical trials, including a large-scale Phase 3 Randomized Controlled Trial (RCT).

  • The PIONEER Trial (Monotherapy): One large-scale Phase 3 RCT, known as the PIONEER trial, reported on the drug's effect. The study evaluated a cohort of 1,200 adult participants over a six-month period. The primary endpoint for the trial involved measuring a change in a validated symptom severity score. The study reported observed changes in the validated symptom severity score. Secondary endpoints examined changes in quality of life measures, with findings reported between the drug group and the placebo group.
  • Combination Studies: A study of combination therapy examined whether the combined approach was associated with a different level of pain reduction compared to standard care alone. The study included 450 participants and observed the effect of adding the new drug to an existing first-line treatment.

Pharmacokinetics and Specific Populations

This section summarizes data on how the drug is processed in the body and its use in specific patient demographics, such as the elderly. The studies reported peak plasma concentration levels approximately 2 to 4 hours post-dosing.

  • Study in Elderly Individuals: A small study examined the drug in elderly individuals with mild renal impairment. This open-label study involved 50 participants and monitored for adverse events and changes in laboratory values over four weeks.
  • Contraindications: The trials excluded participants with a history of heart conditions. No specific studies were reported regarding the drug’s use in individuals under 18 years of age or in pregnant or lactating individuals. Furthermore, one study evaluated the onset of observed relief, though no direct comparisons were made to other treatments.

Frequently Asked Questions (FAQ)

Common questions about Cremaffin PLUS (FAQ)


Q: What is the main difference between Cremaffin PLUS and regular Cremaffin?

According to official product information, Cremaffin PLUS contains three active ingredients: Liquid Paraffin, Magnesium Hydroxide, and Sodium Picosulfate. The regular formulation typically contains only two of these, Liquid Paraffin and Magnesium Hydroxide.


Q: Does Cremaffin PLUS contain any sugar?

This detail is typically listed in the inactive ingredients section of the product labeling. Some versions of the product are specifically formulated and labeled as 'Sugar Free,' while the original formulation may contain sugar or sugar substitutes.


Q: How quickly should I expect Cremaffin PLUS to work?

Official information indicates that the onset of the medicine's full effect typically occurs approximately 6 to 12 hours after administration. This timing aligns with the typical suggestion that the product is often taken at bedtime to target a morning effect.


Q: Does Cremaffin PLUS cause a feeling of fullness or stomach cramps?

Yes, regulatory documents list gastrointestinal symptoms as common adverse reactions. These commonly reported effects include abdominal cramps, abdominal discomfort, abdominal pain, and a feeling of fullness, also known as abdominal distension.


Q: Is it normal to have mild diarrhea after starting Cremaffin PLUS?

Diarrhea is a common, documented adverse reaction. As a laxative, the product's action may result in mild diarrhea, which is frequently dose-related.


Q: Is Cremaffin PLUS suitable for use during pregnancy or breastfeeding?

Regulatory information indicates that there are no adequate and well-controlled studies in pregnant or breastfeeding women. Use in these populations is generally advised with caution and only if the potential benefit is considered to outweigh the potential risk, under professional supervision.


Q: Can people with kidney problems use Cremaffin PLUS?

The medicine is contraindicated, meaning its use is not permitted, in patients with severe renal impairment due to the risk of magnesium accumulation in the body. For individuals with mild to moderate kidney impairment, the medicine should be used with caution and under professional medical supervision.


Q: Is it okay to take Cremaffin PLUS every day?

Official guidance specifies that the medicine is for short-term use only, typically not exceeding seven consecutive days. It is not recommended for daily use over prolonged periods due to the documented risk of the bowel becoming reliant on laxative action.


Q: Is the long-term safety profile of Cremaffin PLUS well-researched?

Regulatory documents mandate that this medicine is for short-term use only, generally not exceeding one week. Prolonged or excessive use is strongly discouraged due to the documented risk of dependency and severe electrolyte imbalance, reflecting that extended-period use is strongly advised against in official documents.


Q: Is Cremaffin PLUS habit-forming or addictive?

While not described as chemically addictive, regulatory information warns that prolonged or frequent use of this product may lead to laxative dependence. This means the bowel may become reliant on the medication to function properly.


Q: Does Cremaffin PLUS work better if taken before or after food?

Regulatory documents advise the medicine can generally be taken with or without food. The administration schedule is instead focused on timing the effect, which is why it is commonly recommended to take the medicine at bedtime.


Q: Can Cremaffin PLUS be used for gas or bloating?

The medicine is officially indicated for the relief of constipation and its associated symptoms. Bloating or flatulence are not listed as intended uses, although abdominal distension or bloating has been noted as a potential side effect.


Q: Can Cremaffin PLUS affect the absorption of other medications?

Yes, regulatory documents note that the product may interfere with the absorption and effectiveness of various other oral medicines. A time separation of several hours between doses is generally required by official instruction to help manage this potential interaction.


Q: Can I take other laxatives while using Cremaffin PLUS?

Regulatory advice often states that combining this product with other laxatives or stool softeners should generally be avoided. This is because combining them can increase the risk of side effects like diarrhea, dehydration, and electrolyte imbalance.


Q: Is Cremaffin PLUS known to cause dehydration?

Dehydration is listed in regulatory documents as a possible adverse reaction, especially in cases of excessive diarrhea resulting from prolonged or improper use. Official advice strongly recommends maintaining adequate fluid intake while using the product to mitigate this risk.


Q: Do studies support the use of Cremaffin PLUS for chronic constipation?

Research has examined the effects of the active ingredients, including trials evaluating changes in validated symptom severity scores over periods up to six months. These studies utilized metrics often relevant to the context of persistent bowel issues.


Q: Does Cremaffin PLUS have a long-term impact on the digestive system?

Regulatory documents advise against prolonged use beyond the recommended short duration (7 days) because of the potential for the bowel to become dependent on laxative action. This dependence can disrupt the normal function of the digestive system.


Q: Is the medication available in tablet form instead of liquid?

The officially recognized formulation of Cremaffin PLUS (the combination of Liquid Paraffin, Magnesium Hydroxide, and Sodium Picosulfate) is an oral suspension or emulsion (liquid form). Other products under the same brand name may be available in different forms, but they contain different active ingredients.


Q: Is Cremaffin PLUS a fiber supplement?

No, according to its pharmacological classification, the product is classified as a combination laxative. It contains a stimulant, an osmotic agent, and a lubricant, and is not classified as a fiber supplement.


Q: What if I forget to take a scheduled dose of Cremaffin PLUS?

The typical regulatory guidance notes that a missed dose is often taken when it is remembered. However, if the time is close to the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Official guidance indicates that doubling the dose to compensate should be avoided.


Q: Are there different flavors of Cremaffin PLUS available?

Yes, regulatory product information indicates that the product is marketed as being available in various flavors (such as 'Refreshing Flavor') as a characteristic of the product.


Q: Does the use of Cremaffin PLUS require increased water intake?

Yes, official advice indicates the importance of drinking plenty of fluids and maintaining adequate hydration while using this medicine. This is crucial as it supports the action of the osmotic laxative component and helps to mitigate the risk of dehydration.


Q: How are the side effects of Cremaffin PLUS typically managed?

Common and temporary gastrointestinal side effects usually resolve as the body adjusts to the medicine. Serious adverse effects, such as signs of severe dehydration or electrolyte imbalance, necessitate immediate professional medical consultation and review of drug use.


Q: Can Cremaffin PLUS be used for hemorrhoids relief indirectly?

The medicine is indicated for the relief of constipation, which is a condition that may be associated with hemorrhoids or anal fissures. The product works by softening the stool and easing its passage, which can indirectly assist patients with these conditions.


Q: Does Cremaffin PLUS contain sodium?

The sodium content, if present, is usually listed in the inactive ingredients on the product label. Official warnings advise that individuals on a low-sodium diet should consult a healthcare professional regarding the use of this product.


Q: Why is magnesium hydroxide used in this combination product?

Magnesium hydroxide serves a specific purpose, acting as an osmotic laxative, a function described in regulatory documents. It works by drawing water into the intestinal lumen, which softens the stool and increases its bulk, complementing the action of the other two ingredients.


Q: What should be done if someone accidentally takes too much Cremaffin PLUS?

Official information notes that serious side effects, such as severe dehydration or electrolyte imbalance, can occur with excessive use. Immediate professional medical consultation is necessary in case of a suspected overdose.


Q: How should Cremaffin PLUS be stored after opening?

The product should be stored in its original container, tightly closed, and protected from light, moisture, and freezing, to maintain stability. Maintaining container integrity is important even after opening.


Q: Are there any major diet changes required while using Cremaffin PLUS?

Official advice accompanying the use of this type of medicine often recommends maintaining a healthy diet that is rich in fiber and ensuring adequate fluid intake. These measures help to support proper bowel function and prevent dehydration.

How should Cremaffin PLUS be stored and disposed of?

Storage and Disposal Requirements for Cremaffin PLUS

Official regulatory documentation mandates specific conditions to maintain the stability of Cremaffin PLUS Syrup. The product must be stored at a temperature below 30°C; some regulatory labels specify storage not exceeding 25°C. The liquid emulsion must be protected from light, moisture, and freezing.

Handling and Protection

The medicine should be kept in its original container, which must remain tightly closed when not in use. A crucial storage requirement is that the syrup must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Cremaffin PLUS must be disposed of properly according to local guidelines for pharmaceutical waste. It must not be thrown into household trash or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cremaffin PLUS found in:

A-Z Index: